scholarly journals Regulatory T cells and type 2 innate lymphoid cell-dependent asthma

Allergy ◽  
2017 ◽  
Vol 72 (8) ◽  
pp. 1148-1155 ◽  
Author(s):  
J. L. Aron ◽  
O. Akbari
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Lymphoid Cell ◽  
Innate Lymphoid Cell

scholarly journals Cutting Edge: Maresin-1 Engages Regulatory T Cells To Limit Type 2 Innate Lymphoid Cell Activation and Promote Resolution of Lung Inflammation

2014 ◽  
Vol 194 (3) ◽  
pp. 863-867 ◽  
Author(s):  
Nandini Krishnamoorthy ◽  
Patrick R. Burkett ◽  
Jesmond Dalli ◽  
Raja-Elie E. Abdulnour ◽  
Romain Colas ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Lymphoid Cell ◽  
Lung Inflammation ◽  
Cell Activation ◽  
Cutting Edge ◽  
Innate Lymphoid Cell ◽  
Maresin 1

scholarly journals LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis

Immunity ◽  
2018 ◽  
Vol 49 (2) ◽  
pp. 342-352.e5 ◽  
Author(s):  
David Bauché ◽  
Barbara Joyce-Shaikh ◽  
Renu Jain ◽  
Jeff Grein ◽  
Karin S. Ku ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Lymphoid Cell ◽  
Innate Lymphoid Cell ◽  
Group 3 ◽  
Interleukin 23

scholarly journals T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function

2018 ◽  
Vol 12 (1) ◽  
pp. 51-63 ◽  
Author(s):  
N. Garrido-Mesa ◽  
J-H. Schroeder ◽  
E. Stolarczyk ◽  
A. L. Gallagher ◽  
J. W. Lo ◽  
...  
Keyword(s):  
Immune Responses ◽  
Intestinal Mucosa ◽  
Lymphoid Cell ◽  
Cell Function ◽  
Innate Lymphoid Cell

Abstract P288: Systemic Administration of an Angiotensin Type-2 Receptor Agonist Decreases Renal Regulatory T Cells

Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
Ellen E Gillis ◽  
Jennifer C Sullivan
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Critical Role ◽  
High Dose ◽  
Ang Ii ◽  
Osmotic Minipump ◽  
Angiotensin Type 2 Receptor ◽  
Angiotensin Type

There is increasing evidence supporting a critical role of the immune system in the development of hypertension. Our lab has previously reported sex differences in the renal T cell profile in both Spontaneously Hypertensive Rats (SHR) and Angiotensin II (Ang II) models of hypertension, with females having more anti-inflammatory regulatory T cells (Tregs) than males. Ang II has a well-defined role in the activation of pro-inflammatory T cells in hypertension via the angiotensin type-1 receptor (AT1R). Less is known about the role of the angiotensin type-2 receptor (AT2R) in the regulation of immune cells, although the AT2R has been shown to be cardioprotective and AT2R expression is greater in females than males. Based on the potential anti-hypertensive role of AT2Rs, we hypothesized that administration of an AT2R agonist, Compound 21 (C21), would increase renal Tregs, and this increase would be greater in females due to greater AT2R expression. Male and female SHR (10 weeks of age, n=3-4) were implanted with telemetry units for continuous monitoring of mean arterial pressure (MAP). Following 10 days of recovery, baseline MAP was recorded for 5 days. Rats were then divided into the following treatment groups: surgical controls, low dose C21 (150 ng/kg/min, sc by osmotic minipump), high dose C21 (300 ng/kg/min, sc by osmotic minipump). Kidneys were harvested after 2 weeks of treatment and flow cytometry was performed on whole kidney homogenates. MAP was not altered by C21 treatment in males (137±4 vs 134±4 vs 134±4 mmHg; n.s.) or females (128±2 vs 136±5 vs 134±4 mmHg; n.s.). Interestingly, despite having no effect on MAP, there was a significant decrease in renal CD3 + CD4 + FoxP3 + Tregs in females following both low and high doses of C21 (data expressed as % CD3 + CD4 + cells: 6±0.6 vs 3±0.6 vs 3.5±1.3 %, respectively; p=0.02). Tregs decrease in males following the high dose of C21 only (data expressed as % CD3 + CD4 + cells: 3.3±0.3 vs 3.3±0.5 vs 1.7±0.7 %, respectively; p=0.05). Total CD3 + T cells, CD3 + CD4 + T cells, and Th17 cells were not altered by C21 treatment. In conclusion, AT2R activation suppresses renal Tregs, and females are more sensitive than males. These data suggest a novel role for AT2R regulation in the kidney in hypertension.

Regulatory T-cells dysregulation in type 2 diabetic nephropathy

2019 ◽  
Vol 19 (1) ◽  
pp. 19
Author(s):  
WalaaH.M Ibrahim ◽  
MostafaG Aly ◽  
AhmadB Ahmad ◽  
NohaG Sayed ◽  
HebaS Galal ◽  
...  
Keyword(s):  
T Cells ◽  
Diabetic Nephropathy ◽  
Regulatory T Cells ◽  
Type 2 Diabetic

scholarly journals In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors

Immunity ◽  
2020 ◽  
Vol 53 (4) ◽  
pp. 775-792.e9 ◽  
Author(s):  
Patrice Zeis ◽  
Mi Lian ◽  
Xiying Fan ◽  
Josip S. Herman ◽  
Daniela C. Hernandez ◽  
...  
Keyword(s):  
Lymphoid Cell ◽  
Innate Lymphoid Cell

scholarly journals 2019 ATVB Plenary Lecture

2020 ◽  
Vol 40 (4) ◽  
pp. 853-864 ◽  
Author(s):  
Tian X. Zhao ◽  
Stephen A. Newland ◽  
Ziad Mallat
Keyword(s):  
Cardiovascular Disease ◽  
T Cells ◽  
Regulatory T Cells ◽  
Immune Responses ◽  
Interleukin 2 ◽  
Cell Types ◽  
Innate Lymphoid Cells ◽  
Lymphoid Cells ◽  
Myocardial Repair

Regulatory T cells and type-2 innate lymphoid cells represent 2 subsets of immune cells, which have been shown in preclinical models to be important in atherosclerosis and myocardial repair. Regulatory T cells play a crucial role in immune homeostasis and tolerance via their interactions with effector T cells, dendritic cells, and monocytes/macrophages. They also utilize and secrete inhibitory cytokines, including interleukin 10 and transforming growth factor β, to regulate or suppress pathogenic immune responses. Type-2 innate lymphoid cells have an important role in type-2 immune responses and tissue repair through secreting interleukins 5 and 13, as well as a variety of biological mediators and growth factors. Intriguingly, interleukin-2 has emerged as a common cytokine, which can be harnessed to upregulate both cell types, and also has important translational consequences as clinical trials are ongoing for its use in cardiovascular disease. Here, we briefly review the biology of these regulatory immune cell types, discuss the preclinical and clinical evidence for their functions in cardiovascular disease, examine the prospects for clinical translation and current ongoing trials, and finally, postulate how overlap in the mechanisms of upregulation may be leveraged in future treatments for patients.

Sign in / Sign up

Export Citation Format

Share Document